About this trial
The human amniotic membrane (hAM) patch, introduced by Rizzo et al. in 2018, showed a 100% anatomical success rate for large or failed macular holes over a 6-month follow-up. Despite its regenerative properties like promoting angiogenesis and having low immunogenicity, its clinical use is limited by challenges such as trimming to fit small holes and complications during insertion. To overcome these issues, decellularized amniotic membrane (dAM) has been processed into a hydrogel form, enhancing its applicability and allowing it to be used as an injectable hydrogel for minimally invasive therapies. While dAM hydrogels have been used in various medical fields, their application in intraocular surgery is new. This study proposes using dAM hydrogel for large macular hole closure, comparing its effectiveness to the inverted ILM flap technique in a randomized controlled trial.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
>18 years old
idiopathic full thickness macular hole > 400 micron of diameter
phakic or pseudophakic
absence of systemic adverse conditions
Disqualifiers
idiopathic full thickness macular hole > 1,500 micron of diameter
traumatic macular holes
myopic macular holes,
concomitant retinal and other ocular disease
Trial design
Parallel
Treatments tested in this trial
25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade
Procedure/SurgeryStandard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. "Flower petal" type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole
25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade
Procedure/SurgeryStandard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining then filling the hole with amniotic membrane hydrogel and sulfur hexafluoride (SF6) tamponade
Treatment groups
Trial outcomes
Primary outcomes
Best corrected visual acuity (BCVA)
Difference of best corrected visual acuity (BCVA) after primary vitrectomy for idiopathic full thickness macular holes with inverted flap technique versus internal limiting membrane (ILM) peeling technique
Closure rate
Closure rate after primary vitrectomy for idiopathic full thickness macular holes with decellularized amniotic membrane hydrogel versus inverted flap technique
Sponsors and contacts
Click on the lead sponsor to view all of their trials.